Immune Response and Safety of SARS-CoV-2 mRNA-1273 Vaccine in Patients With Myasthenia Gravis

This study provides Class IV evidence that patients with MG receiving the mRNA-1273 vaccine did not show clinical worsening after vaccination and that most of the patients achieved high cellular or immune response levels.

Source: Neurology Neuroimmunology and Neuroinflammation - June 21, 2022 Category: Neurology Authors: Reyes-Leiva, D., Lopez-Contreras, J., Moga, E., Pla-Junca, F., Lynton-Pons, E., Rojas-Garcia, R., Turon-Sans, J., Querol, L., Olive, M., Alvarez-Velasco, R., Caballero-Avila, M., Carbayo, A., Vesperinas-Castro, A., Domingo, P., Illa, I., Gallardo, E., Cor Tags: Autoimmune diseases, Myasthenia, Class IV, COVID-19 Research Article Source Type: research